The Journal of infectious diseases
October 1, 2026 · via Europe PMC
Concordance Between Fingerprick and Venous Whole Blood CD4 Counts Using the Visitect CD4 Advanced Disease Platform.
Adzemovic T, Nalintya E, Onencan P, +5 more, Rajasingham R.
AI summary — for doctors, generated from the abstract only
A fingerprick Visitect CD4 test gave the same above/below-200 result as venous blood in most patients.
What was studied
Prospective validation of a rapid semi-quantitative CD4 test (cutoff 200 cells/uL) comparing fingerprick with venous whole blood samples.
Key findings
- Overall agreement between fingerprick and venous results was 95.5% (149 of 156).
- The assay only classifies results as above or below 200 cells/uL.
Clinical relevance
Where venepuncture and lab CD4 testing are hard to access, a fingerprick point-of-care test could help identify advanced HIV disease quickly.
Who should care
Limitations
The abstract is brief, with a small sample (156) and no detail on setting, discordant cases, or sensitivity and specificity against a reference standard.
Fingerprick Visitect CD4 can reasonably be used for advanced-disease triage when venous sampling is impractical, ideally confirming discordant or borderline cases.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
The Visitect CD4 Advanced Disease platform is a rapid, semi-quantitative assay that estimates CD4 results above or below 200 cells/μL and can be performed on venous whole blood or by fingerprick. We conducted a prospective validation of the Visitect CD4 Advanced Disease platform via fingerprick versus venous whole blood. Overall, there was 95.5% agreement (149/156). The high level of agreement between the fingerprick and venous whole blood results may support the use of the fingerprick Visitect CD4 test as a reliable point-of-care diagnostic tool in settings where access to conventional venous whole blood testing may be limited.
DOI
10.1093/infdis/jiag437
PMID
42636100
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed